{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T06:37:51Z","timestamp":1781419071036,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.077","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T14:31:00Z","timestamp":1493994660000},"page":"3171-3177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect"],"prefix":"10.1016","volume":"35","author":[{"given":"Xiangming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriya","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.077_b0005","series-title":"Vaccines. New approaches to immunological problems","first-page":"363","article-title":"Adenovirus based expression vectors and recombinant vaccines","author":"Graham","year":"1992"},{"issue":"404","key":"10.1016\/j.vaccine.2017.04.077_b0010","first-page":"410","article-title":"Transfer of genes to humans: early lessons and obstacles to success","volume":"270","author":"Crystal","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.077_b0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/infdis\/124.2.155","article-title":"Immunization with live type 7 and 4 vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans","volume":"124","author":"Top","year":"1971","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.077_b0020","first-page":"185","article-title":"Control of adenovirus acute respiratory disease in U.S. Army trainees","volume":"48","author":"Top","year":"1975","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.vaccine.2017.04.077_b0025","first-page":"367","article-title":"Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines","volume":"77","author":"Chaloner-Larsson","year":"1986","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2017.04.077_b0030","unstructured":"Schaechter M, Medoff G. Eisenstein BI. Adenoviruses. In: Mechanisms of Microbial Disease, Second Edition. USA: Williams and Wilkins; 1993. p. 493."},{"key":"10.1016\/j.vaccine.2017.04.077_b0035","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.04.077_b0040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","article-title":"Toward an understanding of NKT cell biology: progress and paradoxes","volume":"23","author":"Kronenberg","year":"2005","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nri2451","article-title":"Harnessing invariant NKT cells in vaccination strategies","volume":"9","author":"Cerundolo","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1146\/annurev.immunol.22.012703.104608","article-title":"CD1: antigen presentation and T cell function","volume":"22","author":"Brigl","year":"2004","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0060","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.4049\/jimmunol.0900858","article-title":"Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin","volume":"183","author":"Venkataswamy","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0065","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.vaccine.2008.02.002","article-title":"Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide","volume":"26","author":"Huang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.077_b0070","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.4049\/jimmunol.175.5.3309","article-title":"Alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor","volume":"175","author":"Ko","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0075","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.171.10.5140","article-title":"NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells","volume":"171","author":"Hermans","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.04.077_b0085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1084\/jem.20011889","article-title":"Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines","volume":"195","author":"Gonzalez-Aseguinolaza","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.04.077_b0090","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.1006662107","article-title":"Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant","volume":"107","author":"Li","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.04.077_b0095","doi-asserted-by":"crossref","first-page":"e78407","DOI":"10.1371\/journal.pone.0078407","article-title":"A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates","volume":"8","author":"Padte","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.077_b0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clim.2010.11.009","article-title":"Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant","volume":"140","author":"Padte","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.04.077_b0105","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/mt.2014.109","article-title":"Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations","volume":"22","author":"Kimani","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2017.04.077_b0110","doi-asserted-by":"crossref","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults","volume":"6","author":"Sedegah","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.077_b0115","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","article-title":"Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component","volume":"6","author":"Tamminga","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.077_b0120","doi-asserted-by":"crossref","first-page":"e55571","DOI":"10.1371\/journal.pone.0055571","article-title":"DNA prime\/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity","volume":"8","author":"Chuang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.077_b0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jim.2012.10.019","article-title":"Generation of tissue-specific H-2Kd transgenic mice for the study of K(d)-restricted malaria epitope-specific CD8+ T-cell responses in vivo","volume":"387","author":"Huang","year":"2013","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2017.04.077_b0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cbic.200390009","article-title":"Total enantioselective synthesis and in vivo biological evaluation of a novel fluorescent BODIPY alpha-galactosylceramide","volume":"4","author":"Vo-Hoang","year":"2003","journal-title":"ChemBioChem"},{"key":"10.1016\/j.vaccine.2017.04.077_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2007.03.006","article-title":"Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d","volume":"323","author":"Yu","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2017.04.077_b0140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/intimm\/3.6.579","article-title":"CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria","volume":"3","author":"Rodrigues","year":"1991","journal-title":"Int Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T03:54:04Z","timestamp":1535860444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17305789"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}